Therapy Areas: Vaccines
Pfizer likely to file emergency use filing for COVID-19 vaccine in late November 2020
16 October 2020 -

US pharmaceutical company Pfizer Inc (NYSE:PFE) said it may file for authorisation of the COVID-19 vaccine it is developing with German partner BioNTech in late November, 20220, Reuters news agency reported on Friday.

This makes it unlikely a COVID-19 vaccine will be available before US elections as President Donald Trump has promised.

Pfizer said the regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November 2020.

Chief Executive Officer of Pfizer, Albert Bourla, was quoted as saying in an open letter posted on the company's website that based on current trial enrolment and dosing in a late-stage trial, the company expects to have that safety data in the third week of November 2020.

Bourla noted in the letter that the filing depended on several other factors, including initial data on effectiveness that may or may not be available by late October 2020, adding that the company plans to share efficacy data with the public as soon as practical.